National Institute on Drug Abuse; Notice of Closed Meetings, 14572-14573 [E9-6787]

Download as PDF tjames on PRODPC61 with NOTICES 14572 Federal Register / Vol. 74, No. 60 / Tuesday, March 31, 2009 / Notices Agenda: To review and evaluate grant applications. Place: Hilton—DC/Rockville, 1750 Rockville Pike, Rockville, MD 20852. Contact Person: Michael B. Small, PhD, Scientific Review Officer, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Blvd., Room 8127, Bethesda, MD 20892–8328. 301–402–0996. smallm@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, NCI Clinical Studies. Date: June 15–17, 2009. Time: 3 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852. Contact Person: Majed M. Hamawy, PhD, MBA, Scientific Review Officer, Research Programs Review Branch, Division of Extramual Activities, National Cancer Institute, NIH, 6116 Executive Boulevard, Room 8135, Bethesda, MD 20852. 301–594– 5659. mh101v@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, Cancer Prevention, Control and Population Sciences. Date: June 16–17, 2009. Time: 8 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Hilton—Rockville, 1750 Rockville Pike, Rockville, MD 20852. Contact Person: Wlodek Lopaczynski, MD, PhD, Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8131, Bethesda, MD 20892. 301–594–1402. lopacw@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, SPORE Review. Date: June 16–18, 2009. Time: 4 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852. Contact Person: Shamala K. Srinivas, PhD, Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8123, Bethesda, MD 20892, 301–594–1224, ss537t@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, Application Use of Transformative Emerging Technologies in Cancer Research. Date: June 22–23, 2009. Time: 8 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814. Contact Person: Viatcheslav A. Soldatenkov, MD, PhD, Scientific Review Officer, Special Review And Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8050a, Bethesda, MD 20892– VerDate Nov<24>2008 14:35 Mar 30, 2009 Jkt 217001 8329, 301–451–4758, soldatenkovv@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: March 24, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–7206 Filed 3–30–09; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meeting will he closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Loan Repayment. Date: March 30, 2009. Time: 9 a.m. to 5p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Lyle Furr, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, (301) 435–1439, lf33c.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Mouse Gene Development Initiative. Date: May 6, 2009. Time: 8 a.m. to 5 p.m. PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 Agenda: To review and evaluate grant applications. Place: Doubletree Hotel, 8120 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Minna Liang, PhD, Scientific Review Officer, Training and Special Projects Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, 6101 Executive Blvd., Room 220, MSC 8401, Bethesda, MD 20852, 301–435–1432, liangm@nida.nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Brain Imaging Studies of Negative Reinforcement in Humans. Date: May 29, 2009. Time: 8:30 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015. Contact Person: Kristen V Huntley, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, 301–435–1433, huntleyk@mail.nih.gov. Name of Committee: National Institute on Drug Abuse Initial Review Group; Health Services Research Subcommittee. Date: June 9–10, 2009, Time: 8:30 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Madison Lowes Hotel, 1177 Fifteenth Street, NW., Washington, DC 20005. Contact Person: Meenaxi Hiremath, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301–402–7964, mh392g@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: March 20, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–6781 Filed 3–30–09; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meeting will be closed to the public in accordance with the E:\FR\FM\31MRN1.SGM 31MRN1 Federal Register / Vol. 74, No. 60 / Tuesday, March 31, 2009 / Notices tjames on PRODPC61 with NOTICES provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Medication Discovery Using Rat Models of Relapse. Date: April 14, 2009. Time: 9 a.m. to 3 p.m. Agenda: To review and evaluate contract proposals. Place: Courtyard by Marriott Rockville, 2500 Research Boulevard, Rockville, MD 20850. Contact Person: Lyle Furr, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, (301) 435–1439. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Use of I/M Cross-Section and m/z as a Unique Identifier of Lipids and Neuropeptides in Complex Biosamples. Date: April 15, 2009. Time: 9 a.m. to 12 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Lyle Furr, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, (301) 435–1439, lf33c.nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; National Hispanic Science Network. Date: April 16, 2009. Time: 11 a.m. to 1 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Minna Liang, PhD, Scientific Review Officer, Training and Special Projects Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, 6101 Executive Blvd., Room 220, MSC 8401, Bethesda, MD 20852, 301–435–1432, liangm@nida.nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Educational Marketing. Date: April 28, 2009. Time: 9:30 a.m. to 12 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). VerDate Nov<24>2008 14:35 Mar 30, 2009 Jkt 217001 Contact Person: Lyle Furr, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, (301) 435–1439, lf33c.nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Long Acting Bup for Opiate Maintenance. Date: April 29, 2009. Time: 1 p.m. to 3 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Scott Chen, PhD, Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Boulevard, Room 220, MSC 8401, Bethesda, MD 20892, 301–443–9511, chensc@mail.nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Novel Azetidine CB1 Antagonists. Date: May 6, 2009. Time: 9:30 a.m. to 12:30 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Lyle Furr, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, (301) 435–1439, lf33c.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: March 20, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–6787 Filed 3–30–09; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 14573 and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; Rheumatic Disease Clinical Research Grant Review. Date: March 31, 2009. Time: 1 p.m. to 2 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Kan Ma, PhD, Scientific Review Officer, NIH/NIAMS, EP Review Branch, One Democracy Plaza Suite 800, Bethesda, MD 20892–4872, 301–594–4952, mak2@mail.nih.gov. Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; Research Project (R01) and Clinical Trial Planning (R34) Grant Review. Date: April 15, 2009. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Eric H. Brown, PhD, Scientific Review Administrator, National Institute of Arthritis and Musculoskeletal, and Skin Diseases, 6701 Democracy Blvd, Suite 824, Bethesda, MD 20892, (301) 594– 4955, browneri@mail.nih.gov. Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; Loan Repayment Program Review. Date: April 30, 2009. Time: 10 a.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Kan Ma, PhD, Scientific Review Officer, MH/NIAMS EP Review Branch, One Democracy Plaza Suite 800, Bethesda, MD 20892–4872, 301–594–4952, mak2@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS) Dated: March 23, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–6929 Filed 3–30–09; 8:45 am] BILLING CODE 4140–01–M E:\FR\FM\31MRN1.SGM 31MRN1

Agencies

[Federal Register Volume 74, Number 60 (Tuesday, March 31, 2009)]
[Notices]
[Pages 14572-14573]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-6787]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meetings.
    The meeting will be closed to the public in accordance with the

[[Page 14573]]

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Medication Discovery Using Rat Models of Relapse.
    Date: April 14, 2009.
    Time: 9 a.m. to 3 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: Courtyard by Marriott Rockville, 2500 Research Boulevard, 
Rockville, MD 20850.
    Contact Person: Lyle Furr, Contract Review Specialist, Office of 
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 
Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-
8401, (301) 435-1439.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Use of I/M Cross-Section and m/z as a Unique 
Identifier of Lipids and Neuropeptides in Complex Biosamples.
    Date: April 15, 2009.
    Time: 9 a.m. to 12 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852 (Telephone Conference Call).
    Contact Person: Lyle Furr, Contract Review Specialist, Office of 
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 
Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-
8401, (301) 435-1439, lf33c.nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; National Hispanic Science Network.
    Date: April 16, 2009.
    Time: 11 a.m. to 1 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852 (Telephone Conference Call).
    Contact Person: Minna Liang, PhD, Scientific Review Officer, 
Training and Special Projects Review Branch, Office of Extramural 
Affairs, National Institute on Drug Abuse, NIH, 6101 Executive 
Blvd., Room 220, MSC 8401, Bethesda, MD 20852, 301-435-1432, 
liangm@nida.nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Educational Marketing.
    Date: April 28, 2009.
    Time: 9:30 a.m. to 12 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852 (Telephone Conference Call).
    Contact Person: Lyle Furr, Contract Review Specialist, Office of 
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 
Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-
8401, (301) 435-1439, lf33c.nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Long Acting Bup for Opiate Maintenance.
    Date: April 29, 2009.
    Time: 1 p.m. to 3 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852 (Telephone Conference Call).
    Contact Person: Scott Chen, PhD, Scientific Review Officer, 
Office of Extramural Affairs, National Institute on Drug Abuse, 
National Institutes of Health, DHHS, 6101 Executive Boulevard, Room 
220, MSC 8401, Bethesda, MD 20892, 301-443-9511, 
chensc@mail.nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Novel Azetidine CB1 Antagonists.
    Date: May 6, 2009.
    Time: 9:30 a.m. to 12:30 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852 (Telephone Conference Call).
    Contact Person: Lyle Furr, Contract Review Specialist, Office of 
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 
Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-
8401, (301) 435-1439, lf33c.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: March 20, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-6787 Filed 3-30-09; 8:45 am]
BILLING CODE 4140-01-M
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.